

Antibody Collaboration and Licensing Deals 2016-2023

https://marketpublishers.com/r/AC55B66724AEN.html

Date: November 2023

Pages: 950

Price: US\$ 3,995.00 (Single User License)

ID: AC55B66724AEN

Abstracts

SUMMARY

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2016 to 2023

DESCRIPTION

Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibody deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1812 antibody deals announced since 2016 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.



The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016

Browse antibody collaboration and licensing deals



Benchmark analysis – identify market value of transactions

Financials terms - upfront, milestone, royalties

Directory of deals by company A-Z, deal type and therapy area

Leading deals by value

Most active dealmakers

Identify assets and deal terms for each transaction

Access contract documents - insights into deal structures

Due diligence - assess suitability of your proposed deal terms for partner companies

Save hundreds of hours of research time

Report scope

Antibody Collaboration and Licensing Deals is intended to provide the reader with an indepth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

Trends in antibody dealmaking in the biopharma industry

Directory of antibody deal records covering pharmaceutical and biotechnology

The leading antibody deals by value

Most active antibody licensing dealmakers

Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.



Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?



BENEFITS

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016

Browse precision medicine in oncology collaboration and licensing deals

Benchmark analysis – identify market value of transactions

Financials terms - upfront, milestone, royalties

Directory of deals by company A-Z, deal type and therapy area

Leading deals by value

Most active dealmakers

Identify assets and deal terms for each transaction

Access contract documents - insights into deal structures

Due diligence - assess suitability of your proposed deal terms for partner companies

Save hundreds of hours of research time



Contents

Executive Summary

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN ANTIBODY DEALMAKING

- 2.1. Introduction
- 2.2. Antibody deals over the years
- 2.3. Most active antibody dealmakers
- 2.4. Antibody deals by deal type
- 2.5. Antibody deals by therapy area
- 2.6. Antibody deals by industry sector
- 2.7. Deal terms for antibody deals
- 2.7.1 Antibody deals headline values
- 2.7.2 Antibody deal upfront payments
- 2.7.3 Antibody deal milestone payments
- 2.7.4 Antibody royalty rates

CHAPTER 3 – LEADING ANTIBODY DEALS

- 3.1. Introduction
- 3.2. Top antibody deals by value

CHAPTER 4 – MOST ACTIVE ANTIBODY DEALMAKERS

- 4.1. Introduction
- 4.2. Most active antibody dealmakers
- 4.3. Most active antibody deals company profiles

CHAPTER 5 – ANTIBODY CONTRACTS DEALMAKING DIRECTORY

- 5.1. Introduction
- 5.2. Antibody contracts dealmaking directory

CHAPTER 6 - ANTIBODY DEALMAKING BY TECHNOLOGY TYPE



Deal directory

Deal directory - Antibody deals by company A-Z

Deal directory – Antibody deals by deal type

Deal directory – Antibody deals by therapy area

Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering



Table Of Figures

TABLE OF FIGURES

- Figure 2: Active antibody dealmaking activity 2016 2023
- Figure 3: Antibody deals by deal type since 2016
- Figure 4: Antibody deals by therapy area since 2016
- Figure 5: Antibody deals by industry sector since 2016
- Figure 6: Antibody deals with a headline value
- Figure 7: Antibody deals with an upfront value
- Figure 8: Antibody deals with a milestone value
- Figure 9: Antibody deals with a royalty rate value
- Figure 10: Top antibody deals by value since 2016
- Figure 11: Most active antibody dealmakers 2016 2023
- Figure 12: Antibody deals by technology type since 2016



I would like to order

Product name: Antibody Collaboration and Licensing Deals 2016-2023

Product link: https://marketpublishers.com/r/AC55B66724AEN.html

Price: US\$ 3,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/AC55B66724AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970